OMASPECT – Sponsored by Hoffmann-La Roche

Active Study | Duration: 96 weeks

OMASPECT is a multicenter, open-label extension study for the treatment of age-related macular degeneration (AMD). This study evaluates the long-term safety and tolerability of intravitreal Lampalizumab for treatment of geographic atrophy (GA) secondary to AMD. Lampalizumab is a monoclonal antibody directed against complement factor D, which plays a role in the complement-mediated destruction of retinal layers as seen in GA. This study is for patients rolled over from the original SPECTRI trial who have completed their Week 96 visit.

Trials are in progress under the direction of Clinical Research Coordinator Maya Talatory (301-656-8100/

Return to Age-Related Macular Degeneration